NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
4d
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment ...
Syndax Pharmaceuticals is now a commercial-stage biopharma with two FDA-approved drugs: Revuforj and Niktimvo. Syndax's Revuforj leads in efficacy for AML, with rapid market penetration and a ...
– 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80% of patients remain on trial as of data cutoff, ...
Kura Oncology And Kyowa Kirin Report Combination Data For KOMZIFTITM (Ziftomenib) With Venetoclax And Azacitidine In Newly Diagnosed And Relapsed/Refractory AML. – 86% (32/37) CRc and 73% (27/37) CR ...
Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial, evaluating ziftomenib in combination with the standard chemotherapy regimen of cytarabine and daunorubicin (7+3) ...
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...
The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback